Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 14, 2006

Sigma-Aldrich Inks Transcriptome Licensing Deal with Rubicon Genomics

  • Sigma-Aldrich signed an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize their TransPlex™ whole transcriptome amplification (WTA) technology. TransPlex can be used to amplify total RNA from a variety of sample sources, such as animals, plants, and microorganisms, according to Sigma. Under the terms of the agreement, Rubicon retains all rights to TransPlex for molecular diagnostics.

    TransPlex WTA creates a cDNA library from the isolated RNA template and then amplifies the library in a single PCR reaction. The TransPlex reagents and protocols, optimized to ensure a linear representation of all expressed genes and exons, allow RNA samples to be amplified 1,000–10,000 fold in less than four hours, explains John Langmore, vp of commercial development at Rubicon.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »